IRCT2012092910964N1已完成2 期
The effectiveness of Rivastigmine on reducing the symptoms of Tardive dyskinesia in patients with Schizophrenia
niversity of Social Welfare and Rehabilitation Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- Male
入选标准
- •Age range between 18 to 65 years, Spent at least one year of treatment with antipsychotics, to have a stable condition of the patient for at least one month prior to study entry.
- •Exclusion criteria: Organic brain disease, Any neurological disorders, Having a chronic health problem, Change in the amount or type of antipsychotic medication or tranquilizers were used during the last 6 months so that might affect the patient's motor symptoms, Patients with mental retardation, Patients with thyroid disorders, Diabetes, and Substance Abusers.
排除标准
- 未提供
研究者
相似试验
招募中
3 期
Effectiveness of Rivastigmine and Donepezil on cognitive disordersIRCT20210819052232N1Esfahan University of Medical Sciences165
招募中
2 期
The Efficacy of Rivastigmine Augementation to Antipsychotic Agents on Positive and Negative Symptoms and Quality of Life in Patients with Chronic SchizophreniaParanoid schizophreniaChronic schizophrenia.F20.0IRCT20190530043769N1Tabriz University of Medical Sciences60
招募中
3 期
Evaluation of the effect of rivastigmine on male patients with chronic schizophreniaIRCT20120314009297N8Mazandaran University of Medical Sciences60
招募中
3 期
Evaluation the effectiveness of rivastigmine and memantine in improving cognitive problems due to electroconvulsive therapyPsychiatric disorders with electroconvulsive therapy (ECT) indication.IRCT20190119042417N2Shahid Beheshti University of Medical Sciences45
已完成
2 期
Efficacy of rivastigmin in the treatment of major depressive disorderIRCT2017020132236N4Vice chancellor for research, Mazandaran University of Medical Sciences20